153 related articles for article (PubMed ID: 38259203)
1. Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk.
Arefan D; Zuley ML; Berg WA; Yang L; Sumkin JH; Wu S
Radiology; 2024 Jan; 310(1):e230269. PubMed ID: 38259203
[TBL] [Abstract][Full Text] [Related]
2. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
3. Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score.
Zhang M; Sadinski M; Haddad D; Bae MS; Martinez D; Morris EA; Gibbs P; Sutton EJ
Front Oncol; 2020; 10():595820. PubMed ID: 33614481
[TBL] [Abstract][Full Text] [Related]
4. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
Wu S; Berg WA; Zuley ML; Kurland BF; Jankowitz RC; Nishikawa R; Gur D; Sumkin JH
Breast Cancer Res; 2016 Jul; 18(1):76. PubMed ID: 27449059
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk.
Niell BL; Abdalah M; Stringfield O; Raghunand N; Ataya D; Gillies R; Balagurunathan Y
AJR Am J Roentgenol; 2021 Jul; 217(1):64-75. PubMed ID: 32876474
[No Abstract] [Full Text] [Related]
6. Automated rating of background parenchymal enhancement in MRI of extremely dense breasts without compromising the association with breast cancer in the DENSE trial.
Wang H; H M van der Velden B; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
Eur J Radiol; 2024 Jun; 175():111442. PubMed ID: 38583349
[TBL] [Abstract][Full Text] [Related]
7. Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study.
Watt GP; Thakran S; Sung JS; Jochelson MS; Lobbes MBI; Weinstein SP; Bradbury AR; Buys SS; Morris EA; Apte A; Patel P; Woods M; Liang X; Pike MC; Kontos D; Bernstein JL
Radiology; 2023 Sep; 308(3):e230367. PubMed ID: 37750771
[TBL] [Abstract][Full Text] [Related]
8. Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: Association with BRCA status.
Goodburn R; Kousi E; Sanders C; Macdonald A; Scurr E; Bunce C; Khabra K; Reddy M; Wilkinson L; O'Flynn E; Allen S; Schmidt MA
Eur Radiol; 2023 Sep; 33(9):6204-6212. PubMed ID: 37017702
[TBL] [Abstract][Full Text] [Related]
9. The Association of Background Parenchymal Enhancement at Breast MRI with Breast Cancer: A Systematic Review and Meta-Analysis.
Thompson CM; Mallawaarachchi I; Dwivedi DK; Ayyappan AP; Shokar NK; Lakshmanaswamy R; Dwivedi AK
Radiology; 2019 Sep; 292(3):552-561. PubMed ID: 31237494
[TBL] [Abstract][Full Text] [Related]
10. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
11. Machine learning-based prediction of future breast cancer using algorithmically measured background parenchymal enhancement on high-risk screening MRI.
Saha A; Grimm LJ; Ghate SV; Kim CE; Soo MS; Yoon SC; Mazurowski MA
J Magn Reson Imaging; 2019 Aug; 50(2):456-464. PubMed ID: 30648316
[TBL] [Abstract][Full Text] [Related]
12. Background Parenchymal Enhancement at Postoperative Surveillance Breast MRI: Association with Future Second Breast Cancer Risk.
Lee SH; Jang MJ; Yoen H; Lee Y; Kim YS; Park AR; Ha SM; Kim SY; Chang JM; Cho N; Moon WK
Radiology; 2023 Jan; 306(1):90-99. PubMed ID: 36040335
[TBL] [Abstract][Full Text] [Related]
13. Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study.
Mao N; Yin P; Zhang H; Zhang K; Song X; Xing D; Chu T
Br J Radiol; 2021 Nov; 94(1127):20210348. PubMed ID: 34520235
[TBL] [Abstract][Full Text] [Related]
14. A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models.
Saha A; Harowicz MR; Wang W; Mazurowski MA
J Cancer Res Clin Oncol; 2018 May; 144(5):799-807. PubMed ID: 29427210
[TBL] [Abstract][Full Text] [Related]
15. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
16. DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence.
Wu S; Zuley ML; Berg WA; Kurland BF; Jankowitz RC; Sumkin JH; Gur D
Sci Rep; 2017 May; 7(1):2115. PubMed ID: 28522877
[TBL] [Abstract][Full Text] [Related]
17. Assessing Quantitative Parenchymal Features at Baseline Dynamic Contrast-enhanced MRI and Cancer Occurrence in Women with Extremely Dense Breasts.
Wang H; van der Velden BHM; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
Radiology; 2023 Aug; 308(2):e222841. PubMed ID: 37552061
[TBL] [Abstract][Full Text] [Related]
18. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
Wu S; Weinstein SP; DeLeo MJ; Conant EF; Chen J; Domchek SM; Kontos D
Breast Cancer Res; 2015 May; 17():67. PubMed ID: 25986460
[TBL] [Abstract][Full Text] [Related]
20. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
